Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Short Interest Update

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGRGet Rating) was the target of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 2,200,000 shares, a growth of 76.0% from the March 15th total of 1,250,000 shares. Based on an average daily volume of 908,900 shares, the days-to-cover ratio is presently 2.4 days.

Several institutional investors have recently added to or reduced their stakes in EIGR. UBS Group AG boosted its holdings in Eiger BioPharmaceuticals by 62.7% in the third quarter. UBS Group AG now owns 3,786 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 1,459 shares during the last quarter. Royal Bank of Canada boosted its holdings in Eiger BioPharmaceuticals by 58.7% in the third quarter. Royal Bank of Canada now owns 4,669 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 1,727 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in Eiger BioPharmaceuticals in the fourth quarter valued at approximately $44,000. BNP Paribas Arbitrage SA boosted its holdings in Eiger BioPharmaceuticals by 84.5% in the third quarter. BNP Paribas Arbitrage SA now owns 6,814 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 3,120 shares during the last quarter. Finally, The Manufacturers Life Insurance Company bought a new stake in Eiger BioPharmaceuticals in the fourth quarter valued at approximately $60,000. 71.01% of the stock is owned by institutional investors.

Several equities research analysts recently weighed in on the stock. StockNews.com started coverage on shares of Eiger BioPharmaceuticals in a research report on Thursday, March 31st. They set a “sell” rating for the company. Zacks Investment Research downgraded Eiger BioPharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, March 16th.

NASDAQ EIGR traded down $0.23 during trading on Friday, hitting $7.05. 2,115,136 shares of the company’s stock were exchanged, compared to its average volume of 1,212,863. The company has a current ratio of 3.46, a quick ratio of 3.37 and a debt-to-equity ratio of 0.33. The company has a market cap of $244.21 million, a PE ratio of -6.98 and a beta of 1.55. Eiger BioPharmaceuticals has a fifty-two week low of $3.53 and a fifty-two week high of $10.02. The stock’s 50 day moving average price is $6.31 and its two-hundred day moving average price is $6.04.

Eiger BioPharmaceuticals (NASDAQ:EIGRGet Rating) last released its quarterly earnings data on Thursday, March 10th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.67) by $0.03. Eiger BioPharmaceuticals had a negative return on equity of 80.40% and a negative net margin of 279.34%. The company had revenue of $3.36 million during the quarter, compared to the consensus estimate of $2.73 million. During the same quarter in the prior year, the firm posted ($0.58) earnings per share. Analysts forecast that Eiger BioPharmaceuticals will post -2.36 earnings per share for the current fiscal year.

Eiger BioPharmaceuticals Company Profile (Get Rating)

Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.

Read More

Receive News & Ratings for Eiger BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.